Rosuvastatin does not affect human apolipoprotein A-I expression in genetically modified mice: A clue to the disputed effect of statins on HDL

British Journal of Pharmacology

Volumn 164, Issue 5, 2011, Pages 1460-1468

  Marchesi, Marta ^a   Parolini, Cinzia ^a   Caligari, Silvia ^a   Gilio, Donatella ^a   Manzini, Stefano ^a   Busnelli, Marco ^a   Cinquanta, Paola ^a   Camera, Marina ^a   Brambilla, Marta ^a   Sirtori, Cesare R ^a   Chiesa, Giulia ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

cholesterol; HDL; human apolipoprotein A I; rosuvastatin; transgenic mice

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; ROSUVASTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOA 1 GENE; ARTICLE; CELLULAR DISTRIBUTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG MECHANISM; GENE EXPRESSION; IN VIVO STUDY; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN SECRETION; LIVER CELL; MALE; MARKER GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TRANSGENIC MOUSE;

ANIMALS; APOLIPOPROTEIN A-I; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CHOLESTEROL; CHOLESTEROL, HDL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROBENZENES; HEPATOCYTES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHOSPHOLIPID TRANSFER PROTEINS; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; SULFONAMIDES; TRIGLYCERIDES;

EID: 80054023174     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01429.x     Document Type: Article

References (40)

1. Asztalos BF, Schaefer EJ, (2003). High-density lipoprotein subpopulations in pathologic conditions. Am J Cardiol 91: 12E-17E. (Pubitemid 36385070)
2. Azrolan N, Odaka H, Breslow JL, Fisher EA, (1995). Dietary fat elevates hepatic apoA-I production by increasing the fraction of apolipoprotein A-I mRNA in the translating pool. J Biol Chem 270: 19833-19838.
3. Barter PJ, Rye KA, (2006). Relationship between the concentration and antiatherogenic activity of high-density lipoproteins. Curr Opin Lipidol 17: 399-403. (Pubitemid 44079477)
4. Bays HE, Ose L, Fraser N, Tribble N, Quinto K, Rejes R, et al,. (2004). A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 26: 1758-1773. (Pubitemid 40089489)
5. Berthou L, Duverger N, Emmanuel F, Langouet S, Auwerx J, Guillouzo A, et al,. (1996). Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest 97: 2408-2416. (Pubitemid 26187327)
6. Bradford MM, (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
7. Brewer HB Jr, Remaley AT, Neufeld EB, Basso F, Joyce C, (2004). Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol 24: 1755-1760. (Pubitemid 39350289)
8. Brown WV, Bays HE, Hassman DR, McKenney J, Chitra R, Hutchinson H, et al,. (2002). Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J 144: 1036-1043. (Pubitemid 36026917)
9. Brown MS, Goldstein JL, (1986). A receptor-mediated pathway for cholesterol homeostasis. Science 232: 34-47. (Pubitemid 16037973)
10. Capuzzi DM, Morgan JM, Weiss RJ, Chitra RR, Hutchinson HG, Cressman MD, (2003). Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol 91: 1304-1310. (Pubitemid 36593473)
11. Chiesa G, Parolini C, Canavesi M, Colombo N, Sirtori CR, Fumagalli R, et al,. (1998). Human apolipoproteins A-I and A-II in cell cholesterol efflux: studies with transgenic mice. Arterioscler Thromb Vasc Biol 18: 1417-1423. (Pubitemid 28421879)
12. Dallinga-Thie GM, van Tol A, Dullaart RP, (2009). Plasma pre beta-HDL formation is decreased by atorvastatin treatment in type 2 diabetes mellitus: role of phospholipid transfer protein. Biochim Biophys Acta 1791: 714-718.
13. Davidson M, McKenney J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R, et al,. (1997). Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol 79: 1475-1481. (Pubitemid 27251065)
14. Davidson M, Ma P, Stein EA, Gotto AM Jr, Raza A, Chitra R, et al,. (2002a). Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 89: 268-275. (Pubitemid 34113787)
15. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, et al,. (2002b). Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 40: 2125-2134. (Pubitemid 36005898)
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285: 2486-2497.
17. van Gent T, van Tol A, (1990). Automated gel permeation chromatography of plasma lipoproteins by preparative fast protein liquid chromatography. J Chromatogr 525: 433-441. (Pubitemid 20058973)
18. Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ, (2000). Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 20: 189-197. (Pubitemid 30048363)
19. Gordon DJ, Rifkind BM, (1989). High-density lipoprotein-the clinical implications of recent studies. N Engl J Med 321: 1311-1316. (Pubitemid 19267219)
20. de Haan W, van der Hoogt CC, Westerterp M, Hoekstra M, Dallinga-Thie GM, Princen HM, et al,. (2008). Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. Atherosclerosis 197: 57-63. (Pubitemid 351273273)
21. Havel RJ, Eder HA, Bragdon JH, (1955). The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34: 1345-1353.
22. Hayek T, Ito Y, Azrolan N, Verdery RB, Aalto-Setala K, Walsh A, et al,. (1993). Dietary fat increases high density lipoprotein (HDL) levels both by increasing the transport rates and decreasing the fractional catabolic rates of HDL cholesterol ester and apolipoprotein (Apo) A-I. Presentation of a new animal model and mechanistic studies in human Apo A-I transgenic and control mice. J Clin Invest 91: 1665-1671. (Pubitemid 23127371)
23. Hunninghake DB, Stein EA, Bays HE, Rader DJ, Chitra RR, Simonson SG, et al,. (2004). Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia. Coron Artery Dis 15: 115-123. (Pubitemid 38453382)
24. Ikewaki K, Terao Y, Ozasa H, Nakada Y, Tohyama J, Inoue Y, et al,. (2009). Effects of atorvastatin on nuclear magnetic resonance-defined lipoprotein subclasses and inflammatory markers in patients with hypercholesterolemia. J Atheroscler Thromb 16: 51-56.
25. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al,. (2003). Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 92: 152-160. (Pubitemid 36835963)
26. Klein A, Deckert V, Schneider M, Dutrillaux F, Hammann A, Athias A, et al,. (2006). Alpha-tocopherol modulates phosphatidylserine externalization in erythrocytes: relevance in phospholipid transfer protein-deficient mice. Arterioscler Thromb Vasc Biol 26: 2160-2167. (Pubitemid 44253803)
27. Maejima T, Yamazaki H, Aoki T, Tamaki T, Sato F, Kitahara M, et al,. (2004). Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun 324: 835-839. (Pubitemid 39345591)
28. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, et al,. (2001). Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 107: 1423-1432. (Pubitemid 32522036)
29. McTaggart F, Jones P, (2008). Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit. Cardiovasc Drugs Ther 22: 321-338.
30. Nichols AV, Krauss RM, Musliner TA, (1986). Nondenaturing polyacrylamide gradient gel electrophoresis. Methods Enzymol 128: 417-431. (Pubitemid 16100908)
31. NRC (National Research Council), Institute of Laboratory Animal Research, Commission on Life Sciences (1996). Guide for the care and use of laboratory animals. National Academy Press: Washington DC.
32. Ooi EM, Watts GF, Nestel PJ, Sviridov D, Hoang A, Barrett PH, (2008). Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome. J Clin Endocrinol Metab 93: 430-437. (Pubitemid 351240812)
33. Qin S, Koga T, Ganji SH, Kamanna VS, Kashyap ML, (2008). Rosuvastatin selectively stimulates apolipoprotein A-I but not apolipoprotein A-II synthesis in Hep G2 cells. Metabolism 57: 973-979. (Pubitemid 351814690)
34. Rotllan N, Llaverias G, Julve J, Jauhiainen M, Calpe-Berdiel L, Hernandez C, et al,. (2011). Differential effects of gemfibrozil and fenofibrate on reverse cholesterol transport from macrophages to feces in vivo. Biochim Biophys Acta 1811: 104-110.
35. Rubin EM, Ishida BY, Clift SM, Krauss RM, (1991). Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc Natl Acad Sci U S A 88: 434-438. (Pubitemid 21915479)
36. Schultz JR, Gong EL, McCall MR, Nichols AV, Clift SM, Rubin EM, (1992). Expression of human apolipoprotein A-II and its effect on high density lipoproteins in transgenic mice. J Biol Chem 267: 21630-21636.
37. Srivastava RA, He S, Newton RS, (2011). Differential regulation of human apolipoprotein AI and high-density lipoprotein by fenofibrate in hapoAI and hapoAI-CIII-AIV transgenic mice. Biochim Biophys Acta 1811: 76-83.
38. Vega GL, Grundy SM, (1998). Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men. Am J Cardiol 81: 36B-42B. (Pubitemid 28113944)
39. Verges B, Florentin E, Baillot-Rudoni S, Petit JM, Brindisi MC, Pais de Barros JP, et al,. (2009). Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes. J Lipid Res 50: 1209-1215.
40. Williamson R, Lee D, Hagaman J, Maeda N, (1992). Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I. Proc Natl Acad Sci U S A 89: 7134-7138.